4503.T
現在値
2,264.00JPY変化
--(--)本日のレンジ
-
--52週レンジ
-
2,360.50∙ 約20分前の相場を表示しています。
May 12 (Reuters) - FDA ::FDA APPROVES NOVEL DRUG TO TREAT MODERATE TO SEVERE HOT FLASHES CAUSED BY MENOPAUSE.FDA: PRESCRIBING INFORMATION FOR VEOZAH INCLUDES A WARNING FOR ELEVATED HEPATIC TRANSAMINASE, OR LIVER INJURY.FDA: BEFORE USING VEOZAH, PATIENTS SHOULD HAVE BLOOD WORK DONE TO TEST FOR LIVER DAMAGE OR INFECTION.
May 11 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS PHARMA INC - CONFIRMS FINAL FEDERAL CIRCUIT DECISION IN LEXISCAN 0.4 MG/ML U.S. PATENT APPEAL.
May 1 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS PHARMA INC: ASTELLAS ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE IVERIC BIO.
April 30 (Reuters) - IVERIC bio Inc <ISEE.O>::ASTELLAS ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE IVERIC BIO.IVERIC BIO INC SAYS ACQUISITION PRICE OF US$40 PER SHARE IN CASH, REPRESENTING A TOTAL EQUITY VALUE OF APPROXIMATELY US$5.9 BILLION.IVERIC BIO INC SAYS IVERIC BIO WILL BECOME AN INDIRECTLY WHOLLY-OWNED SUBSIDIARY OF ASTELLAS.
April 11 (Reuters) - Astellas Pharma Inc <4503.T>::NOTICE REGARDING IMPAIRMENT LOSS AND REVISION OF FINANCIAL FORECASTS FOR FY2022.EXPECTS TO BOOK AN IMPAIRMENT LOSS OF APPROXIMATELY 58.0 BILLION YEN IN Q4.IMPAIRMENT LOSS INCLUDES IMPACT OF REVIEW OF EVRENZO PLANS.
April 3 (Reuters) - Seagen Inc <SGEN.O>::FDA GRANTS ACCELERATED APPROVAL FOR PADCEV® (ENFORTUMAB VEDOTIN-EJFV) WITH KEYTRUDA® (PEMBROLIZUMAB) FOR FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER.FDA GRANTS ACCELERATED APPROVAL FOR PADCEV® (ENFORTUMAB VEDOTIN-EJFV) WITH KEYTRUDA® (PEMBROLIZUMAB) FOR FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER.
March 21 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS ANNOUNCES POSITIVE FINDINGS FROM PHASE 3 GLOW TRIAL OF ZOLBETUXIMAB DURING MARCH ASCO PLENARY SERIES.ASTELLAS PHARMA INC - DATA SHOWS INVESTIGATIONAL ZOLBETUXIMAB PLUS CAPOX REDUCED RISK OF PROGRESSION OR DEATH BY 31.3% VERSUS CAPOX ALONE.ASTELLAS PHARMA INC - STUDY ALSO SHOWED THAT ZOLBETUXIMAB PLUS CAPOX SIGNIFICANTLY PROLONGED OVERALL SURVIVAL, REDUCING RISK OF DEATH BY 22.9%.
March 16 (Reuters) - Astellas Pharma Inc <4503.T>::TO RETIRE TREASURY SHARES WORTH 1.44% OF OUTSTANDING STOCK ON MARCH 29.COMPLETED SHARE BUYBACKS PLANNED FOR FEB 7-MARCH 24.
March 14 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS PHARMA INC: ANNOUNCES PHASE 3 CHINA ARCHES STUDY OF XTANDI MEETS PRIMARY ENDPOINT.
March 1 (Reuters) - Astellas Pharma Inc <4503.T>::: BOUGHT BACK 15. 1 MILLION OWN SHARES WORTH 29 BILLION YEN FROM FEB 7 TO 28.
金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。